The possibilities of improving the clinical use of direct oral anticoagulants
Annals of the Russian academy of medical sciences · 17.03.2026 · 80 (6) · 475-481
DOI: 10.15690/vramn18111 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of the Russian academy of medical sciences, online erschienen am 17.03.2026. Verfasst von Olga V. Zhukova und 2 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Background
More than 40 million people worldwide suffer from atrial fibrillation. Atrial fibrillation is often combined with chronic heart failure (CHF). All patients with atrial fibrillation and CHF, regardless of the left ventricular ejection fraction, are prescribed anticoagulants. Direct oral anticoagulants (DOACs) apixaban and rivaroxaban are widely used in patients with atrial fibrillation. However, to date, there is very little data comparing these two drugs. Aims — сomparative evaluation of the clinical efficacy and safety profile of DOACs (apixaban and ravaroxaban) in patients based on real clinical practice data.
Methods
The study materials were based on the results of the analysis of commercial data on the use of DOACs (apixaban, rivaroxaban) from the depersonalized Optum Clinformatics Data Mart database for the period from January 1, 2013 to December 31, 2020. The primary efficacy indicator was a comprehensive indicator of ischemic stroke. The primary safety indicator was a comprehensive indicator of gastrointestinal bleeding. Information on adverse reactions was obtained from a specialized website VigiAccess (http://www.vigiaccess.org). As an analytical tool, attribute statistics methods were used to determine the risk of developing a particular condition against the background of using the analyzed drug relative to the comparison drug.
Results
During the analysis of two compared drugs (rivaroxaban versus apixaban), the following values of statistical parameters were obtained: AR — 0.3% (95% CI: 0.08–0.52%); OR — 1.61 (95% CI: 0.43–2.80); PAR — 0.15% (95% CI: 0.03–0.34%). The use of rivaroxaban increases the likelihood of developing ischemic stroke compared to the use of apixaban by 0.15% in the entire population. According to the electronic resource VigiAccess, 174,234 reports of adverse events were identified for apixaban (as of 16.07.2025), and 177,285 similar reports for rivaroxaban as of the same date. Circulatory disorders were noted in the total number of reports in 7% of cases for apixaban, and in 9% for rivaroxaban. Apixaban and rivaroxaban are substrates of both CYP3A4 and P-glycoprotein (P-gp). Coadministration with CYP3A4 and P-gp inhibitors increases plasma concentrations of DOACs and increases the risk of bleeding. Coadministration with CYP3A4 and P-gp inducers decreases plasma concentrations of DOACs and increases the risk of thrombosis and thromboembolic events.
Conclusions
Apixaban and rivaroxaban demonstrate similar efficacy in relation to the primary goal — prevention of stroke and thrombosis. The safety and efficacy of therapy with OPA is determined by optimizing the choice of drug and its dose, taking into account possible drug interactions, and dose adjustment in case of liver and kidney dysfunction.
Zitieren
APA
Zhukova, O. V., Shimanovsky, N. L., & Beregovykh, V. V. (2026). The possibilities of improving the clinical use of direct oral anticoagulants. Annals of the Russian academy of medical sciences, 80(6), 475-481. https://doi.org/10.15690/vramn18111
Vancouver
Zhukova OV, Shimanovsky NL, Beregovykh VV. The possibilities of improving the clinical use of direct oral anticoagulants. Annals of the Russian academy of medical sciences. 2026;80(6):475-481. doi:10.15690/vramn18111
BibTeX
@article{Zhukova2026,
author = {Zhukova, Olga V. and Shimanovsky, Nikolay L. and Beregovykh, Valery V.},
title = {The possibilities of improving the clinical use of direct oral anticoagulants},
journal = {Annals of the Russian academy of medical sciences},
year = {2026},
volume = {80},
number = {6},
pages = {475--481},
doi = {10.15690/vramn18111}
}
EUVIMED